Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for Ferring’s drug substance intravesical non-replicating gene therapy, Adstiladrin.
The deal will help ensure the long-term future supply of gene therapy. Following the technology transfer, SK pharmteco will be qualified as another source for manufacturing, testing and release of the medicine, subject to FDA approval.
Ferring’s Adstiladrin was FDA-approved in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors.
“SK pharmteco is proud to partner with Ferring Pharmaceuticals as a manufacturer of the breakthrough gene therapy Adstiladrin,” CEO Joerg Ahlgrimm said. “Our integrated approach, incorporating customizable clinical and commercial GMP manufacturing solutions with comprehensive in-proce…